Company Encyclopedia
View More
name
GLORY HEALTH
02329.HK
Glory Health Industry Limited, an investment holding company, engages in the property development business in the People’s Republic of China. The company operates through Property Development, Primary Land Construction and Development Services, Property Investment, and Property Management and Related Services segments. The Property Development segment develops and sells commercial and residential properties. The Primary Land Construction and Development Services segment provides primary land development services, including services for resettlement, and construction of land infrastructure and ancillary public facilities.
1.202 T
02329.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Real Estate DevelopmentIndustry
Industry Ranking57/128
Industry medianD
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-13.52%E
    • Profit Margin-68.90%E
    • Gross Margin1.35%E
  • Growth ScoreD
    • Revenue YoY0.41%C
    • Net Profit YoY-296.08%E
    • Total Assets YoY5.09%C
    • Net Assets YoY-9.43%D
  • Cash ScoreD
    • Cash Flow Margin-145.14%D
    • OCF YoY0.41%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio78.53%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Glory Health Industry Lists Board Directors with HKEX

    Glory Health Industry Limited has updated its list of directors with the Hong Kong Stock Exchange. The Board includes five executive directors and three independent non-executive directors. The company also detailed the composition of its four Board committees, emphasizing its commitment to good corporate governance and transparency.

    Reuters·
    HK
    02329
    +2.56%
    Reuters·
    HK
    02329
    +2.56%

    Glory Health Industry Ltd. Reports Progress on Debt Restructuring and Property Sales to Address Going Concern Issues

    Glory Health Industry Ltd. has reported progress on its debt restructuring and property sales to address concerns raised by auditors regarding its financial viability. The company has completed the Xi’an Guorui Financial Center Building, which is expected to boost property sales and improve cash flow. A RMB1.314 billion loan extension from the Bank of Tianjin has been approved, while negotiations with other creditors continue. Glory Health aims to resolve its financial issues by 2025 and will provide updates as required by law.

    Reuters·
    HK
    02329
    +2.56%
    Reuters·
    HK
    02329
    +2.56%

    "Performance" GLORY HEALTH's half-year loss expands to 225 million RMB

    GLORY HEALTH announced its interim results for the period ending June this year, with a revenue of RMB 324 million, a year-on-year decrease of 67.2%. The loss widened to RMB 225 million, compared to a loss of RMB 58.659 million in the same period last year; the loss per share was 5.07 cents

    AASTOCKS·
    HK
    02329
    +2.56%
    AASTOCKS·
    HK
    02329
    +2.56%

    GLORY HEALTH released its interim results, with a loss attributable to shareholders of 225 million yuan, an increase of 283.88% year-on-year

    GLORY HEALTH released its interim results for the period ending June 30, 2025, reporting revenue of 324 million yuan, a year-on-year decrease of 67.17%; loss attributable to shareholders of 225 million yuan, a year-on-year increase of 283.88%; basic loss per share of 5.07 cents. Revenue from property development was 183 million yuan, a year-on-year decrease of 76.9%. The decrease in revenue was mainly due to a reduction in the area of completed property development delivered and sales

    Zhitong·
    HK
    02329
    +2.56%
    Zhitong·
    HK
    02329
    +2.56%

    Glory Health Industry Ltd. Reports H1 2025 Net Loss of RMB170 Million Amid Revenue of RMB324.2 Million, Contracted Sales at RMB651.1 Million

    Glory Health Industry Ltd. reported a net loss of RMB170 million for H1 2025, with revenue of RMB324.2 million, down from RMB987.5 million in H1 2024. Contracted sales were RMB651.1 million, while property development revenue fell to RMB182.7 million due to market pressures. The company plans to shift its focus to the health industry, leveraging its land reserves of 6,387,065 square meters, primarily located in Beijing.

    Reuters·
    HK
    02329
    +2.56%
    Reuters·
    HK
    02329
    +2.56%
    © 2025 Longbridge｜Disclaimer